Immix Biopharma Investor Presentation Deck
IMMIXBIO™ SMARXT Tissue-Specific™ Platform
Oo
FIM
TME Normalization™ Technology – SMARXT Tissue-Specific Platform Oncology Application
3 Pillars
System-Tissue Biology Model Development
Purpose-Built Physical Biochemistry Engine
Predictive Validation Framework
IMX-110
IMX-111
BIOLOGIC
IMX-120
BIOLOGIC
www.
UT-1 SCFV
GLUT-1 scFv 8
wwww
Effector
molecules
Produced IMX-110, IMX-111, IMX-120
AWA
www
-PEG-PE
-DOX
-CUR
www.
ww
www.
-PEG-PE
-DOX
-CUR
NO
DO
-PEG-PE
www
O
∞
www
www-
O
●●●
S BIOPHARMA
IMMİX
is a negatively-charged Tissue-Specific Therapeutic™M built
on our TME NormalizationTM Technology encapsulating a
synergistic 5:1 ratio of poly-kinase inhibitor and apoptosis
inducer delivered deep into the TME
First Oncology Micelle to achieve "small molecule
penetration
Electrostatic charge attracts to tumor like
a magnet
●
Resulting in 1,200% increase in apoptosis (tumor cell
death) vs. conventional therapies
is a Tissue-Specific Biologic™ built on our TME
Normalization™ Technology with proprietary GLUT1
antibody biomarker targeting facilitating preferential
accumulation in glucose-consuming cancer cells.
Indication:
Colorectal Cancer (CRC)
is a Tissue-Specific Biologic™M with Immune Normalization
Technology encapsulating anti-inflammatory poly-kinase
inhibitors (polyphenols) with proprietary targeting
(GLUT1/ confidential targets) selectively silencing disease-
causing inflammatory bowel immune cells.
63View entire presentation